Despite high expectations, productivity is frustratingly low in biopharmaceutical research and development. Although expenditures have increased, the number of new medicines resulting from human-genome sequencing has not. This means that a broad variety of diseases are not being treated effectively, in the developed or the developing worlds.
Advances in molecular sciences, corresponding to the sequencing of the human genome in the 1980s, led to the identification of all the human proteins — large, complex molecules necessary for many of the body’s functions. Understanding the proteins’ roles then led to greater knowledge of the underlying causes of diseases. For example, mutations, or defects, at specific molecular locations in human DNA were found to be responsible for some cancers, raising the hope of developing successful therapies tailored to individual patients.
Scientists believed that the ability to visualize and understand human biology at a more detailed level would lead to many new medicines. Identifying the defective molecular parts, known as the drug targets, should have made addressing the causes of disease easier, and would revolutionize the pharmaceutical sciences. And so it has — but without increasing the number of new medicines.
Prior to this molecular revolution, scientists discovered medicines by randomly evaluating different chemicals against phenotypes — an organism’s observable characteristics — in authentic biological systems, such as animals or cells. However, unfortunately, the phenotypic strategy is neither efficient nor intellectually satisfying.
The molecular revolution heralded an era in which drug discovery and development would be rational, not random. However, contrary to expectations, the increased efficiency implied by target identification has not increased productivity. Efforts to address the problem have focused on how the target was selected, the candidate drugs’ efficacy in humans, the risk of undesirable side effects and the efficiency of the discovery process — all to little or no avail.
The July issue of Nature Reviews Drug Discovery analyzed how first-in-class medicines — those drugs that successfully established a new class of medicines — were discovered. Despite the emphasis on target-based drug discovery, phenotypic screening produced the lion’s share of the first-in-class small-molecule medicines approved between 1999 and 2008 — 28 phenotypic medicines versus 17 target-based drugs. Considering how strongly biased the industry has been toward target-based drug discovery, that imbalance is highly significant.
The Nature Reviews article proposed that lower productivity partly reflects target-based discovery’s lack of consideration of the molecular complexities of how the drugs work. Knowing the parts of an efficient machine — a watch, an automobile or a computer — is not enough to describe how it works. The parts must collaborate in precise ways to provide accurate time, reliable transportation or processed information.
Biology is infinitely more complex. The phrase “molecular mechanism of action” (MMOA) describes the way that biological parts collaborate to provide an effective and safe medicine. Addressing the MMOA would contribute to reversing the low productivity of target-based discoveries, because merely knowing the identity of a part involved in a defect may not be sufficient to repair a malfunctioning machine.
The target-based approach is analogous to looking for one’s keys in the dark: If they are under a streetlight, they will be easy to find. Many hoped that the molecular revolution would amount to more streetlights for drug discovery. Unfortunately, it appears that this new light, in most cases, is too dim to illuminate the molecular details of the dynamic human biological machine with sufficient specificity to rationalize the design of new medicines.
The random phenotypic process, though less efficient, will ultimately identify medicines that are effective and work to repair disease. The target-based approach, on the other hand, creates only the illusion of greater efficiency; in reality, its promise has been undermined by its inattention to the MMOA.
There are too many molecular possibilities in dynamic human biology to identify a priori the optimal mechanism of molecular intervention. The way forward is to find a method that combines the efficiency of target-based approaches with the authenticity of phenotypic research.
David Swinney is at the Institute for Rare and Neglected Diseases Drug Discovery and was previously director of Virology Biochemical Pharmacology at Roche, Palo Alto, California.
Copyright: Project Syndicate
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
Ursula K. le Guin in The Ones Who Walked Away from Omelas proposed a thought experiment of a utopian city whose existence depended on one child held captive in a dungeon. When taken to extremes, Le Guin suggests, utilitarian logic violates some of our deepest moral intuitions. Even the greatest social goods — peace, harmony and prosperity — are not worth the sacrifice of an innocent person. Former president Chen Shui-bian (陳水扁), since leaving office, has lived an odyssey that has brought him to lows like Le Guin’s dungeon. From late 2008 to 2015 he was imprisoned, much of this